<DOC>
	<DOCNO>NCT00004265</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient recurrent refractory non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Recurrent Refractory Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate response duration patient recurrent refractory non-small cell lung cancer ( NSCLC ) treat second line paclitaxel . II . Determine qualitative quantitative toxicity treatment regimen relapse patient recurrent NSCLC . III . Evaluate time treatment failure overall survival patient population . OUTLINE : Patients receive paclitaxel IV 1 hour weekly 6 week . Courses repeat every 8 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Approximately 30-60 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer document recurrent refractory disease Progressive disease 3 month completion first line chemotherapy OR Progressive disease first line chemotherapy Clinically stable CNS metastasis allow PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL AST great 5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No clinically significant bradyarrhythmias Other : Neuropathy less grade 2 Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : See Disease Characteristics Must least 1 prior first line chemotherapy regimen metastatic locally advanced disease One prior paclitaxel regimen ( every 3 week schedule ) allow progressive disease le 3 month completion therapy At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy ( indicator lesion within radiation port must progress since completion therapy ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>